Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 10, Issue 10, Pages 1349-1356Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2014.949675
Keywords
biomarker; cfDNA; combination biomarkers; companion diagnostics; IL-27; miRNA; neutrophil CD64; presepsin; sepsis; suPAR; TREM-1
Categories
Funding
- NIH [RO1GM064619, RO1GM099773, R01GM108025]
Ask authors/readers for more resources
Biomarkers have great potential to improve the diagnosis and treatment of sepsis. The available literature supports the potential utility of sTREM-1, IL-27, suPAR, neutrophil CD64, presepsin, cfDNA and miRNAs as novel diagnostic, prognostic and treatment response biomarkers. The future of sepsis biomarkers lies in extensive validation studies of such novel biomarkers across heterogeneous populations and exploration of their power in combination. Furthermore, the use of a companion diagnostics model may augment the ability of investigators to identify novel sepsis biomarkers and develop specific therapeutic strategies based on biomarker information.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available